arrow
J

John M. Kirkwood

university of pittsburgh
H指数:137
被引数:9.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years

原发性黑色素瘤假阴性诊断患者的生命损失年数。一项涉及9063例患者、为期28年的德国中央恶性黑色素瘤登记研究的回顾性研究

2026-07-020
OAAI
A phase Ib/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors

一项关于modakafusp alfa单药及联合pembrolizumab治疗晚期或转移性实体瘤的Ib/II期研究

2025-12-090
OAAI
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade

靶向对免疫检查点阻断耐药的黑色素瘤预临床模型的组合疗法方案

2025-09-160
OA
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade–resistant melanoma: Final analysis from a phase 1b study

肿瘤内注射vidutolimod作为单药治疗或与pembrolizumab联用,用于程序性细胞死亡1阻滞剂耐药性黑色素瘤患者的最终分析:一项1b期研究的结果

Cancer
IF5.1
2025-08-030
OAAI
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial

在随机III期CheckMate 76 K试验中,接受完全切除的IIB/C期黑色素瘤患者使用辅助纳武利尤单抗 versus 安慰剂治疗后的患者报告结局。

2025-05-010
OAAI
Dysfunctional CD11c-CD21- extrafollicular memory B cells are enriched in the periphery and tumors of patients with cancer

功能障碍性CD11c⁻CD21⁻生发中心外记忆B细胞在癌症患者的周围组织和肿瘤中富集

2025-02-190
PRE
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial

Pembrolizumab与安慰剂作为切除的IIB或IIC期黑色素瘤的辅助治疗: 来自随机,双盲,3期KEYNOTE-716试验的组织病理学亚组的结果

2024-03-131
OAAI
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery
2024-02-231
OA
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (vol 29, pg 2835, 2023)
2024-01-040
OAAI
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

Tebentafusp治疗转移性葡萄膜黑色素瘤的三年总生存率

2023-12-1449
OA
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (16 OCT, 10.1038/s41591-023-02583-2, 2023 )

nivolumab在切除的IIB/C期黑色素瘤中的辅助治疗: 随机,3期CheckMate 76k试验的主要结果 (10.1038 10月16日/s41591-023-02583-2,2023)

2023-11-030
OAAI
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

nivolumab在切除的IIB/C期黑色素瘤中的辅助治疗: 随机,3期CheckMate 76k试验的主要结果

2023-10-1653
OAAI